Vanda Pharmaceuticals Inc. (VNDA), Wednesday announced that it has received approval from the U.S. Food and Drug Administration for its Investigational New Drug application for its VTR-297 for the treatment of onychomycosis.
Onychomycosis, or tinea unguium, is a fungal infection of the nail, which can cause cosmetic issues as well as decrease peripheral circulation in certain cases.
The company stated that VTR-297 is a small molecule histone deacetylase or HDAC inhibitor that works as an antifungal antibiotic.
At present, Jublia, Kerydin, and Penlac are used for the treatment of onychomycosis.
Currently, Vanda's stock is climbing 0.24 percent, to $3.65 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.